Anti-Human IL-12 (Clone 24910)

Pricing & Details

Product No.I-351
Clone
24910
Protein
IL-12
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Interleukin-12, NKSF, TSF, Maturation Factor, Cytotoxic Lymphocyte Maturation Factor (CLMF), p35
Isotype
Mouse
IgG1
Applications
ICC
,
N
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
I-351-25 µg
25 µg
$195.00
In stock
Max:
Min: 1
Step: 1
I-351-100 µg
100 µg
$440.00
In stock
Max:
Min: 1
Step: 1
I-351-500 µg
500 µg
$935.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Data

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Mouse
Immunogen
Purified Recombinant Sf 21-derived rhIL-12 (>98%)
Endotoxin Level
<0.1 EU/µg
Formulation
This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Storage and Handling
The lyophilized antibody should be stored desiccated at -20°C to -70°C. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
Western Blotting: To detect Human IL-12 this monoclonal antibody can be used at a concentration of 1-2 µg/ml. This monoclonal antibody should be used in conjunction with compatible second-step reagents such as PN:M114 and a chromogenic substrate such as PN:T343. The detection limit for Human IL-12 is 20 ng/lane under non-reducing conditions. Use of this antibody under reducing conditions is not recommended. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:I-535.
Other Applications Reported In Literature ?
Neutralization: Human IL-12 stimulates the 3H-thymidine incorporation by PHA activated human peripheral blood mononuclear cells in a dose-dependent manner1. The ED50 for this effect is typically 0.05 - 0.2 ng/mL. This antibody is useful for neutralization of Human IL-12 bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human IL-12 (at 1.0 ng/ml) is 0.3 - 0.9 µg/ml. The bioassay was perfromed using PHA-activated peripheral blood mononuclear cell (PBMC) proliferation assay.
Immunocytochemistry: This antibody can be used at 8 - 25 μg/mL with the appropriate secondary reagent such as PN:M103 to detect human IL-12 in cultured cells or tissue sections using PN:K107 or PN:D100.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone 24910 recognizes an epitope on human IL-12.
Background
IL-12 plays a role in resistance against pathogens via the differentiation of naive T cells into Th1 cells. It stimulates the growth and function of T cells, blocks formation of new blood vessels, and contributes to antimycobacterial immune response. In addition, it promotes the production of IFN-γ and TNF-α and reduces IL-4 mediated suppression of IFN-γ. Consequently, this enhances the immunostimulatory and immunomodulatory effects of IFN-γ. In addition, there appears to be a link between IL-2 and the signal transduction of IL-12 in NK cells, which enhances the functional response of IL-12 via IFN-γ production and killing of target cells. Furthermore, IL-12 is thought to be associated with autoimmunity. IL-12 was shown to worsen the condition when administered to people already suffering from autoimmune diseases. Comparatively, inhibition of IL-12 (either through IL-12 gene knock-out in mice or treatment of mice with IL-12 mAbs) improved the disease.

Antigen Details

Protein
PubMed

References & Citations

1. Kapsenberg, ML. et al. (1997) J. Immunol. 159: 28
2. Ritz, J. et al. (2001) Blood. 97(12):3860-6.
3. Barnes, PF. et al. (1994) J Clin Invest. 93(4):1733-9.
General Western Blot Protocol

Formats Available

Prod No.
Description
I-351
Products are for research use only. Not for use in diagnostic or therapeutic procedures.